Prognostic value of a systemic inflammatory response (as assessed by markers such as C-reactive protein [CRP], albumin or white cell counts) for overall survival has been indicated in several types of malignancies (e.g. colorectal cancer, pancreatic cancer, breast cancer and prostate cancer) (10), including biliary tract cancer (11). This evidence concerns the gene CRP and breast carcinoma.